世界の抗体薬物コンジュゲート治療市場2020年:企業別、地域別、種類・用途別

【英語タイトル】Global Antibody Drug Conjugate Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが出版した調査資料(GIR20SP01933)・商品コード:GIR20SP01933
・発行会社(調査会社):GlobalInfoResearch
・発行日:2020年9月18日(※2024年版があります。お問い合わせください)
・ページ数:100
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療、製薬、バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、抗体薬物コンジュゲート治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。抗体薬物コンジュゲート治療の種類別市場規模(免疫学技術、免疫原技術、シアトル遺伝学技術、その他)、用途別市場規模(リンパ腫、白血病、多発性骨髄腫、皮膚癌、大腸癌、膠芽腫、膵臓癌、前立腺癌、固形腫瘍、乳癌)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Bayer AG、Sanofi、Seattle Genetics、Pfizer、Synthon Holding、Hoffman-Le Roche、Amgen、Genentech、ImmunoGen、Genmab、Novartis、Eli Lilly
・地域別グローバル市場分析 2015年-2020年
・抗体薬物コンジュゲート治療の北米市場(アメリカ、カナダ、メキシコ)
・抗体薬物コンジュゲート治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・抗体薬物コンジュゲート治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・抗体薬物コンジュゲート治療の南米市場(ブラジル、アルゼンチン)
・抗体薬物コンジュゲート治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:免疫学技術、免疫原技術、シアトル遺伝学技術、その他
・用途別分析:リンパ腫、白血病、多発性骨髄腫、皮膚癌、大腸癌、膠芽腫、膵臓癌、前立腺癌、固形腫瘍、乳癌
・地域別市場規模予測 2021年-2025年
・調査の結果・結論
【レポートの概要】

Market Overview
The Antibody Drug Conjugate Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Antibody Drug Conjugate Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

Market segmentation
Antibody Drug Conjugate Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Antibody Drug Conjugate Therapeutics market has been segmented into:
Mmunomedics Technology
Immunogen Technology
Seattle Genetics Technology
Others

By Application, Antibody Drug Conjugate Therapeutics has been segmented into:
Lymphoma
Leukemia
Multiple Myeloma
Skin Cancer
Colon Cancer
Glioblastoma
Pancreatic Cancer
Prostate Cancer
Solid Tumor
Breast Cancer

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Antibody Drug Conjugate Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Antibody Drug Conjugate Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Antibody Drug Conjugate Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Antibody Drug Conjugate Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Antibody Drug Conjugate Therapeutics Market Share Analysis
Antibody Drug Conjugate Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Antibody Drug Conjugate Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Antibody Drug Conjugate Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Antibody Drug Conjugate Therapeutics are:
Bayer AG
Sanofi
Seattle Genetics
Pfizer
Synthon Holding
Hoffman-Le Roche
Amgen
Genentech
ImmunoGen
Genmab
Novartis
Eli Lilly
Among other players domestic and global, Antibody Drug Conjugate Therapeutics market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

【レポートの目次】

1 Antibody Drug Conjugate Therapeutics Market Overview
1.1 Product Overview and Scope of Antibody Drug Conjugate Therapeutics
1.2 Classification of Antibody Drug Conjugate Therapeutics by Type
1.2.1 Global Antibody Drug Conjugate Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type in 2019
1.2.3 Mmunomedics Technology
1.2.4 Immunogen Technology
1.2.5 Seattle Genetics Technology
1.2.6 Others
1.3 Global Antibody Drug Conjugate Therapeutics Market by Application
1.3.1 Overview: Global Antibody Drug Conjugate Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Lymphoma
1.3.3 Leukemia
1.3.4 Multiple Myeloma
1.3.5 Skin Cancer
1.3.6 Colon Cancer
1.3.7 Glioblastoma
1.3.8 Pancreatic Cancer
1.3.9 Prostate Cancer
1.3.10 Solid Tumor
1.3.11 Breast Cancer
1.4 Global Antibody Drug Conjugate Therapeutics Market by Regions
1.4.1 Global Antibody Drug Conjugate Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Antibody Drug Conjugate Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Antibody Drug Conjugate Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Antibody Drug Conjugate Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Antibody Drug Conjugate Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Antibody Drug Conjugate Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Antibody Drug Conjugate Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 Bayer AG
2.1.1 Bayer AG Details
2.1.2 Bayer AG Major Business
2.1.3 Bayer AG SWOT Analysis
2.1.4 Bayer AG Product and Services
2.1.5 Bayer AG Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi SWOT Analysis
2.2.4 Sanofi Product and Services
2.2.5 Sanofi Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Seattle Genetics
2.3.1 Seattle Genetics Details
2.3.2 Seattle Genetics Major Business
2.3.3 Seattle Genetics SWOT Analysis
2.3.4 Seattle Genetics Product and Services
2.3.5 Seattle Genetics Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer SWOT Analysis
2.4.4 Pfizer Product and Services
2.4.5 Pfizer Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Synthon Holding
2.5.1 Synthon Holding Details
2.5.2 Synthon Holding Major Business
2.5.3 Synthon Holding SWOT Analysis
2.5.4 Synthon Holding Product and Services
2.5.5 Synthon Holding Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Hoffman-Le Roche
2.6.1 Hoffman-Le Roche Details
2.6.2 Hoffman-Le Roche Major Business
2.6.3 Hoffman-Le Roche Product and Services
2.6.4 Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Amgen
2.7.1 Amgen Details
2.7.2 Amgen Major Business
2.7.3 Amgen Product and Services
2.7.4 Amgen Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Genentech
2.8.1 Genentech Details
2.8.2 Genentech Major Business
2.8.3 Genentech Product and Services
2.8.4 Genentech Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 ImmunoGen
2.9.1 ImmunoGen Details
2.9.2 ImmunoGen Major Business
2.9.3 ImmunoGen Product and Services
2.9.4 ImmunoGen Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Genmab
2.10.1 Genmab Details
2.10.2 Genmab Major Business
2.10.3 Genmab Product and Services
2.10.4 Genmab Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.11 Novartis
2.11.1 Novartis Details
2.11.2 Novartis Major Business
2.11.3 Novartis Product and Services
2.11.4 Novartis Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.12 Eli Lilly
2.12.1 Eli Lilly Details
2.12.2 Eli Lilly Major Business
2.12.3 Eli Lilly Product and Services
2.12.4 Eli Lilly Antibody Drug Conjugate Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Antibody Drug Conjugate Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Antibody Drug Conjugate Therapeutics Players Market Share
3.2.2 Top 10 Antibody Drug Conjugate Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Antibody Drug Conjugate Therapeutics Revenue and Market Share by Regions
4.2 North America Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Antibody Drug Conjugate Therapeutics Revenue by Countries
5.1 North America Antibody Drug Conjugate Therapeutics Revenue by Countries (2015-2020)
5.2 USA Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Antibody Drug Conjugate Therapeutics Revenue by Countries
6.1 Europe Antibody Drug Conjugate Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Antibody Drug Conjugate Therapeutics Revenue by Countries
7.1 Asia-Pacific Antibody Drug Conjugate Therapeutics Revenue by Countries (2015-2020)
7.2 China Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Antibody Drug Conjugate Therapeutics Revenue by Countries
8.1 South America Antibody Drug Conjugate Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Antibody Drug Conjugate Therapeutics by Countries
9.1 Middle East & Africa Antibody Drug Conjugate Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Antibody Drug Conjugate Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Antibody Drug Conjugate Therapeutics Market Forecast by Type (2019-2024)
10.3 Mmunomedics Technology Revenue Growth Rate (2015-2025)
10.4 Immunogen Technology Revenue Growth Rate (2015-2025)
10.5 Seattle Genetics Technology Revenue Growth Rate (2015-2025)
10.6 Others Revenue Growth Rate (2015-2025)
11 Global Antibody Drug Conjugate Therapeutics Market Segment by Application
11.1 Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Antibody Drug Conjugate Therapeutics Market Forecast by Application (2019-2024)
11.3 Lymphoma Revenue Growth (2015-2020)
11.4 Leukemia Revenue Growth (2015-2020)
11.5 Multiple Myeloma Revenue Growth (2015-2020)
11.6 Skin Cancer Revenue Growth (2015-2020)
11.7 Colon Cancer Revenue Growth (2015-2020)
11.8 Glioblastoma Revenue Growth (2015-2020)
11.9 Pancreatic Cancer Revenue Growth (2015-2020)
11.10 Prostate Cancer Revenue Growth (2015-2020)
11.11 Solid Tumor Revenue Growth (2015-2020)
11.12 Breast Cancer Revenue Growth (2015-2020)
12 Global Antibody Drug Conjugate Therapeutics Market Size Forecast (2021-2025)
12.1 Global Antibody Drug Conjugate Therapeutics Market Size Forecast (2021-2025)
12.2 Global Antibody Drug Conjugate Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Antibody Drug Conjugate Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Antibody Drug Conjugate Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Antibody Drug Conjugate Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Antibody Drug Conjugate Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Antibody Drug Conjugate Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Antibody Drug Conjugate Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Antibody Drug Conjugate Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Antibody Drug Conjugate Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Antibody Drug Conjugate Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Antibody Drug Conjugate Therapeutics Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Bayer AG Corporate Information, Location and Competitors
Table 7. Bayer AG Antibody Drug Conjugate Therapeutics Major Business
Table 8. Bayer AG Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 9. Bayer AG SWOT Analysis
Table 10. Bayer AG Antibody Drug Conjugate Therapeutics Product and Solutions
Table 11. Bayer AG Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Sanofi Corporate Information, Location and Competitors
Table 13. Sanofi Antibody Drug Conjugate Therapeutics Major Business
Table 14. Sanofi Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2018-2019)
Table 15. Sanofi SWOT Analysis
Table 16. Sanofi Antibody Drug Conjugate Therapeutics Product and Solutions
Table 17. Sanofi Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Seattle Genetics Corporate Information, Location and Competitors
Table 19. Seattle Genetics Antibody Drug Conjugate Therapeutics Major Business
Table 20. Seattle Genetics Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 21. Seattle Genetics SWOT Analysis
Table 22. Seattle Genetics Antibody Drug Conjugate Therapeutics Product and Solutions
Table 23. Seattle Genetics Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Pfizer Corporate Information, Location and Competitors
Table 25. Pfizer Antibody Drug Conjugate Therapeutics Major Business
Table 26. Pfizer Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 27. Pfizer SWOT Analysis
Table 28. Pfizer Antibody Drug Conjugate Therapeutics Product and Solutions
Table 29. Pfizer Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Synthon Holding Corporate Information, Location and Competitors
Table 31. Synthon Holding Antibody Drug Conjugate Therapeutics Major Business
Table 32. Synthon Holding Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 33. Synthon Holding SWOT Analysis
Table 34. Synthon Holding Antibody Drug Conjugate Therapeutics Product and Solutions
Table 35. Synthon Holding Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Hoffman-Le Roche Corporate Information, Location and Competitors
Table 37. Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Major Business
Table 38. Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 39. Hoffman-Le Roche SWOT Analysis
Table 40. Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Product and Solutions
Table 41. Hoffman-Le Roche Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Amgen Corporate Information, Location and Competitors
Table 43. Amgen Antibody Drug Conjugate Therapeutics Major Business
Table 44. Amgen Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 45. Amgen SWOT Analysis
Table 46. Amgen Antibody Drug Conjugate Therapeutics Product and Solutions
Table 47. Amgen Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Genentech Corporate Information, Location and Competitors
Table 49. Genentech Antibody Drug Conjugate Therapeutics Major Business
Table 50. Genentech Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 51. Genentech SWOT Analysis
Table 52. Genentech Antibody Drug Conjugate Therapeutics Product and Solutions
Table 53. Genentech Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. ImmunoGen Corporate Information, Location and Competitors
Table 55. ImmunoGen Antibody Drug Conjugate Therapeutics Major Business
Table 56. ImmunoGen Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 57. ImmunoGen SWOT Analysis
Table 58. ImmunoGen Antibody Drug Conjugate Therapeutics Product and Solutions
Table 59. ImmunoGen Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Genmab Corporate Information, Location and Competitors
Table 61. Genmab Antibody Drug Conjugate Therapeutics Major Business
Table 62. Genmab Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 63. Genmab SWOT Analysis
Table 64. Genmab Antibody Drug Conjugate Therapeutics Product and Solutions
Table 65. Genmab Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Novartis Corporate Information, Location and Competitors
Table 67. Novartis Antibody Drug Conjugate Therapeutics Major Business
Table 68. Novartis Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 69. Novartis SWOT Analysis
Table 70. Novartis Antibody Drug Conjugate Therapeutics Product and Solutions
Table 71. Novartis Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Eli Lilly Corporate Information, Location and Competitors
Table 73. Eli Lilly Antibody Drug Conjugate Therapeutics Major Business
Table 74. Eli Lilly Antibody Drug Conjugate Therapeutics Total Revenue (USD Million) (2017-2018)
Table 75. Eli Lilly SWOT Analysis
Table 76. Eli Lilly Antibody Drug Conjugate Therapeutics Product and Solutions
Table 77. Eli Lilly Antibody Drug Conjugate Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 78. Global Antibody Drug Conjugate Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 79. Global Antibody Drug Conjugate Therapeutics Revenue Share by Players (2015-2020)
Table 80. Global Antibody Drug Conjugate Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 81. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Regions (2015-2020)
Table 82. North America Antibody Drug Conjugate Therapeutics Revenue by Countries (2015-2020)
Table 83. North America Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries (2015-2020)
Table 84. Europe Antibody Drug Conjugate Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 85. Asia-Pacific Antibody Drug Conjugate Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 86. South America Antibody Drug Conjugate Therapeutics Revenue by Countries (2015-2020)
Table 87. South America Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries (2015-2020)
Table 88. Middle East and Africa Antibody Drug Conjugate Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 89. Middle East and Africa Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries (2015-2020)
Table 90. Global Antibody Drug Conjugate Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 91. Global Antibody Drug Conjugate Therapeutics Revenue Share by Type (2015-2020)
Table 92. Global Antibody Drug Conjugate Therapeutics Revenue Forecast by Type (2021-2025)
Table 93. Global Antibody Drug Conjugate Therapeutics Revenue by Application (2015-2020)
Table 94. Global Antibody Drug Conjugate Therapeutics Revenue Share by Application (2015-2020)
Table 95. Global Antibody Drug Conjugate Therapeutics Revenue Forecast by Application (2021-2025)
Table 96. Global Antibody Drug Conjugate Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Antibody Drug Conjugate Therapeutics Picture
Figure 2. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Type in 2019
Figure 3. Mmunomedics Technology Picture
Figure 4. Immunogen Technology Picture
Figure 5. Seattle Genetics Technology Picture
Figure 6. Others Picture
Figure 7. Antibody Drug Conjugate Therapeutics Revenue Market Share by Application in 2019
Figure 8. Lymphoma Picture
Figure 9. Leukemia Picture
Figure 10. Multiple Myeloma Picture
Figure 11. Skin Cancer Picture
Figure 12. Colon Cancer Picture
Figure 13. Glioblastoma Picture
Figure 14. Pancreatic Cancer Picture
Figure 15. Prostate Cancer Picture
Figure 16. Solid Tumor Picture
Figure 17. Global Antibody Drug Conjugate Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 18. North America Antibody Drug Conjugate Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Europe Antibody Drug Conjugate Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Asia-Pacific Antibody Drug Conjugate Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. South America Antibody Drug Conjugate Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 22. Middle East and Africa Antibody Drug Conjugate Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 23. Global Antibody Drug Conjugate Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 24. Global Antibody Drug Conjugate Therapeutics Revenue Share by Players in 2019
Figure 25. Global Top 5 Players Antibody Drug Conjugate Therapeutics Revenue Market Share in 2019
Figure 26. Global Top 10 Players Antibody Drug Conjugate Therapeutics Revenue Market Share in 2019
Figure 27. Key Players Market Share Trend
Figure 28. Global Antibody Drug Conjugate Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 29. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 30. Global Antibody Drug Conjugate Therapeutics Revenue Market Share by Regions in 2018
Figure 31. North America Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Europe Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. Asia-Pacific Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. South America Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 35. Middle East and Africa Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 36. North America Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 37. North America Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries in 2019
Figure 38. USA Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Canada Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. Mexico Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Europe Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 42. Europe Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries in 2019
Figure 43. Germany Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. UK Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. France Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. Russia Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. Italy Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. Asia-Pacific Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 49. Asia-Pacific Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries in 2019
Figure 50. China Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 51. Japan Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. Korea Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 53. India Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 54. Southeast Asia Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. South America Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 56. South America Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries in 2019
Figure 57. Brazil Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. Argentina Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 59. Middle East and Africa Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 60. Middle East and Africa Antibody Drug Conjugate Therapeutics Revenue Market Share by Countries in 2019
Figure 61. Saudi Arabia Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 62. UAE Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 63. Egypt Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 64. South Africa Antibody Drug Conjugate Therapeutics Revenue and Growth Rate (2015-2020)
Figure 65. Global Antibody Drug Conjugate Therapeutics Revenue Share by Type (2015-2020)
Figure 66. Global Antibody Drug Conjugate Therapeutics Revenue Share by Type in 2019
Figure 67. Global Antibody Drug Conjugate Therapeutics Market Share Forecast by Type (2021-2025)
Figure 68. Global Mmunomedics Technology Revenue Growth Rate (2015-2020)
Figure 69. Global Immunogen Technology Revenue Growth Rate (2015-2020)
Figure 70. Global Seattle Genetics Technology Revenue Growth Rate (2015-2020)
Figure 71. Global Others Revenue Growth Rate (2015-2020)
Figure 72. Global Antibody Drug Conjugate Therapeutics Revenue Share by Application (2015-2020)
Figure 73. Global Antibody Drug Conjugate Therapeutics Revenue Share by Application in 2019
Figure 74. Global Antibody Drug Conjugate Therapeutics Market Share Forecast by Application (2021-2025)
Figure 75. Global Lymphoma Revenue Growth Rate (2015-2020)
Figure 76. Global Leukemia Revenue Growth Rate (2015-2020)
Figure 77. Global Multiple Myeloma Revenue Growth Rate (2015-2020)
Figure 78. Global Skin Cancer Revenue Growth Rate (2015-2020)
Figure 79. Global Colon Cancer Revenue Growth Rate (2015-2020)
Figure 80. Global Glioblastoma Revenue Growth Rate (2015-2020)
Figure 81. Global Pancreatic Cancer Revenue Growth Rate (2015-2020)
Figure 82. Global Prostate Cancer Revenue Growth Rate (2015-2020)
Figure 83. Global Solid Tumor Revenue Growth Rate (2015-2020)
Figure 84. Global Breast Cancer Revenue Growth Rate (2015-2020)
Figure 85. Global Antibody Drug Conjugate Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 86. Global Antibody Drug Conjugate Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 87. Global Antibody Drug Conjugate Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 88. North America Antibody Drug Conjugate Therapeutics Revenue Market Forecast (2021-2025)
Figure 89. Europe Antibody Drug Conjugate Therapeutics Revenue Market Forecast (2021-2025)
Figure 90. Asia-Pacific Antibody Drug Conjugate Therapeutics Revenue Market Forecast (2021-2025)
Figure 91. South America Antibody Drug Conjugate Therapeutics Revenue Market Forecast (2021-2025)
Figure 92. Middle East and Africa Antibody Drug Conjugate Therapeutics Revenue Market Forecast (2021-2025)
Figure 93. Sales Channel: Direct Channel vs Indirect Channel


【掲載企業】

Bayer AG、Sanofi、Seattle Genetics、Pfizer、Synthon Holding、Hoffman-Le Roche、Amgen、Genentech、ImmunoGen、Genmab、Novartis、Eli Lilly

★調査レポート[世界の抗体薬物コンジュゲート治療市場2020年:企業別、地域別、種類・用途別] (コード:GIR20SP01933)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の抗体薬物コンジュゲート治療市場2020年:企業別、地域別、種類・用途別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆